Epigenetic Mechanisms Regulating HIV CNS Latency and Neuropathogenesis Using Novel Single Cell Technologies (R01, R21 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to support studies on the epigenetic mechanisms regulating HIV Central Nervous System (CNS) latency and/or neuropathogenesis using in-vitro (macrophages, microglia and astrocytes, organoids), ex-vivo (post-mortem tissues) and in-vivo systems (animal models). Strategies to target epigenetic pathways for achieving sustained HIV remission and treatment of HIV associated-CNS dysfunction are encouraged. The use novel single cell technologies are also strongly encouraged but is not a requirement.  Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborations are encouraged but not required. High risk/high payoff projects that lack preliminary data may be most appropriate for the companion R21 FOA, RFA-MH-22-281  while applicants with preliminary data may wish to apply using the R01 mechanism.


  • Letter of Intent Due Date(s): 30 days prior to the application due date.

  • AIDS Due Date: Dec. 5, 2022

RFA-MH-22-280 Expiration Date December 06, 2022




Medical - Basic Science
Medical - Clinical Science

External Deadline

December 5, 2022